Tumor Microenvironment
Parthenon Therapeutics Launches with $65 Million Series A to Advance Immuno-Oncology Treatment
2021-11-07
Day 1 ESMO 2021 Roundup: Investigational Immunotherapies Show Promise in Early Cancer Trials
2021-09-18
Biotech Duo Revise Co-development & Commercialization Agreement of Intelligent Drug Delivery System
2020-10-08
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23